Mass-spectrometric identification of a novel angiotensin peptide in human plasma

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 2, 2007, Pages 297-302

  Jankowski, Vera ^a   Vanholder, Raymond ^b   Van Der Giet, Markus ^a   Tölle, Markus ^a   Karadogan, Sevil ^a   Gobom, Johan ^c   Furkert, Jens ^a   Oksche, Alexander ^a   Krause, Eberhard ^d   Tran, Thi Nguyet Anh ^f   Tepel, Martin ^a   Schuchardt, Mirjam ^a   Schlüter, Hartmut ^a   Wiedon, Annette ^a   Beyermann, Michael ^d   Bader, Michael ^e   Todiras, Mihail ^d   Zidek, Walter ^a   Jankowski, Joachim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^d LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

^e MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^f Max Delbrück Center for Molecular Medicine ^*

Author keywords

Angiotensin peptide; Human plasma; Mass spectrometry; Vasoconstriction

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN A; ANGIOTENSIN II; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DECARBOXYLATION; DRUG ACTIVITY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; KIDNEY; KIDNEY FAILURE; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MONONUCLEAR CELL; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; RAT; RAT STRAIN; STRUCTURE ANALYSIS; VASOCONSTRICTION;

AGED; ANGIOTENSIN II; ANGIOTENSINS; ANIMALS; CARDIOVASCULAR PHYSIOLOGY; CARDIOVASCULAR SYSTEM; CELL LINE; CELLS, CULTURED; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MASS SPECTROMETRY; MICE; MICE, KNOCKOUT; MIDDLE AGED; RATS; RECEPTOR, ANGIOTENSIN, TYPE 2; VASOCONSTRICTION;

EID: 33846417985     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000253889.09765.5f     Document Type: Article

References (24)

1. Handa RK, Ferrario CM, Strandhoy JW. Renal actions of angiotensin-(1-7): in vivo and in vitro studies. Am J Physiol. 1996;270:F141-F147.
2. Lochard N, Thibault G, Silversides DW, Touyz RM, Reudelhuber TL. Chronic production of angiotensin IV in the brain leads to hypertension that is reversible with an angiotensin II AT1 receptor antagonist. Circ Res. 2004;94:1451-1457.
3. Petrescu G, Gurzu B, Slatineanu SM, Costuleanu M, Costuleanu N. [Interactions between angiotensin-(1-7)and angiotensin II in isolated rat portal vein]. Rev Med Chir Soc Med Nat Iasi. 2003;107:102-107.
4. Ren Y, Garvin JL, Carretero OA. Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension. 2002;39:799-802.
5. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415-472.
6. Ferrario CM, Chappell MC, Dean RH, Iyer SN. Novel angiotensin peptides regulate blood pressure, endothelial function, and natriuresis. J Am Soc Nephrol. 1998;9:1716-1722.
7. Jankowski V, Tölle M, Vanholder R, Schönfelder G, van der Giet M, Henning L, Schlüter H, Paul M, Zidek W, Jankowski J. Identification of uridine adenosine tetraphosphate (Up4A) as an endothelium-derived vasoconstrictive factor. Nature Medicine. 2005;11:223-227.
8. van der Giet M, Khattab M, Borgel J, Schlüter H, Zidek W. Differential effects of diadenosine phosphates on purinoceptors in the rat isolated perfused kidney. Br J Pharmacol. 1997;120:1453-1460.
9. Tepel M, Schlotmann R, Barenbrock M, Kisters K, Klaus T, Spieker C, Walter M, Meyer C, Bretzel RG, Zidek W. Lymphocytic Na(+)-H+ exchange increases after an oral glucose challenge. Circ Res. 1995;77:1024-1029.
10. Giebing G, Tölle M, Jürgensen J, Eichhorst J, Furkert J, Beyermann M, Neuschafer-Rube F, Rosenthal W, Zidek W, van der Giet M, Oksche A. Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction. Circ Res. 2005;97:707-715.
11. Jankowski V, Vanholder R, van der Giet M, Henning L, Tölle M, Schönfelder G, Krakow A, Karadogan S, Gustavsson N, Gobom J, Webb J, Lehrach H, Giebing G, Schlüter H, Hilgers KF, Zidek W, Jankowski J. Detection of angiotensin II in supernatants of stimulated mononuclear leukocytes by MALDI-TOF-TOF-mass analysis. Hypertension. 2005;46:591-597.
12. Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, Smithies O, Coffman TM. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci U S A. 1995;92:3521-3525.
13. Baumelou A, Singlas E, Petitclerc T, Desmichels D, Jacobs C, Soria J. Pharmacokinetics of a low molecular weight heparin (reviparine) in hemodialyzed patients. Nephron. 1994;68:202-206.
14. Follea G, Laville M, Pozet N, Dechavanne M. Pharmacokinetic studies of standard heparin and low molecular weight heparin in patients with chronic renal failure. Haemostasis. 1986;16:147-151.
15. Rebas E, Lachowicz-Ochedalska A. The effect of angiotensin III on protein tyrosine kinase activity in rat pituitary. Regul Pept. 2005;130:14-18.
16. Wright JW, Morseth SL, Abhold RH, Harding JW. Pressor action and dipsogenicity induced by angiotensin II and III in rats. Am J Physiol. 1985;249:R514-R521.
17. Zini S, Fournie-Zaluski MC, Chauvel E, Roques BP, Corvol P, Llorens-Cortes C. Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Proc Natl Acad Sci U S A. 1996;93:11968-11973.
18. Rozenfeld R, Reaux A, Iturrioz X, Fassot C, Fournie-Zaluski MC, David C, Maigret B, Roques BP, Corvol P, Llorens-Cortes C. Aminopeptidase A, generating one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, plays a key role in central control of blood pressure. Proc West Pharmacol Soc. 2003;46:39-44.
19. Yang CR, Phillips MI, Renaud LP. Angiotensin II receptor activation depolarizes rat supraoptic neurons in vitro. Am J Physiol. 1992;263:R1333-R1338.
20. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahashi H, Iwasaka T. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest. 1999;104:925-935.
21. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension. 1998;31:349-355.
22. Tsuzuki S, Matoba T, Eguchi S, Inagami T. Angiotensin II type 2 receptor inhibits cell proliferation and activates tyrosine phosphatase. Hypertension. 1996;28:916-918.
23. Bedecs K, Elbaz N, Sutren M, Masson M, Susini C, Strosberg AD, Nahmias C. Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase. Biochem J. 1997;325:449-454.
24. Horiuchi M, Hayashida W, Akishita M, Tamura K, Daviet L, Lehtonen JY, Dzau VJ. Stimulation of different subtypes of angiotensin II receptors, AT1 and AT2 receptors, regulates STAT activation by negative crosstalk. Circ Res. 1999;84:876-882.